Stock Insider Trading (from SEC Form 4)
MDVX / Medovex Corp. insiders include Lawson James Ronald JR (), and Thomas John C (), ANDREWS JAMES R M D (), Kullmann Patrick C (COO, PRESIDENT), Hennies Clyde A. (), Mogford Jon (), Betz Randal R (), PAPASAN LARRY W (), Sablowski Manfred (SENIOR VICE PRESIDENT), Crowne Jesse () Gorlin Jarrett S (CHIEF EXECUTIVE OFFICER), GORLIN STEVE (), Hills Thomas Edward (), Haufe Scott (), .
Medovex Corp. insider trades are found here. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Job titles are listed as of the filing and may not be current. Click the link icon to see the full transaction history.
Stop missing out on important events!
|Tran Value||Post Value||Percent
Betz Randal R
Thomas John C
ANDREWS JAMES R M D
Hennies Clyde A.
Lawson James Ronald JR
PAPASAN LARRY W
Gorlin Jarrett S
Kullmann Patrick C
Hills Thomas Edward
- Open market or private purchase of non-derivative or derivative security
- Open market or private sale of non-derivative or derivative security
- Grant, award, or other acquisition of securities from the company (such as an option)
- Conversion of derivative
- Sale or transfer of securities back to the company
- Payment of exercise price or tax liability using portion of securities received from the company
- Gift of securities by or to the insider
- Equity swaps and similar hedging transactions
- Exercise or conversion of derivative security received from the company (such as an option)
- A transaction voluntarily reported on Form 4
- Other (accompanied by a footnote describing the transaction)
Related News Stories
Today we will focus on the much anticipated FDA decision on AEterna Zentaris’ (AEZS) Macrilen for diagnosis of adult growth hormone deficiency. (150-5)
Today we will discuss an article on Synergy Pharmaceuticals (SGYP) by John Engle, titled, “Synergy’s New CEO: More Of The Same Or Change Of Course?” (496-2)
LOS ANGELES, CA / ACCESSWIRE / November 21, 2017 / Medovex Corporation (OTCQB: MDVX), the developer of the DenerveX® System, a new and novel device designed for enduring relief of Facet Joint Syndrome related to chronic back pain, a non-addictive, non-opioid drug alternative capable of restoring a patient to a more normal and active lifestyle, today announced that it will be presenting at the 10th annual LD Micro Main Event on Tuesday, December 5, at 2:30PM PST / 5:30 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, California. (19-1)
* Medovex Corp files for non-timely 10-Q - SEC filing Source text: (bit.ly/2AGY46b) Further company coverage: (4-0)